The Deputy Minister of Public Health, Luis Suárez, reported that in the next few days an agreement will be signed with the Gamaleya Institute of Russia to facilitate the purchase of the Sputnik V vaccine when the studies are completed and have the respective certificates.
In a Press release, noted that agreements will also be signed with Novavax and Covaxx for the same scenario, in addition to the confidentiality agreements already signed with the laboratories Pfizer, Johnson & Johnson, Moderna, Oxford and AstraZeneca.
The official pointed out that Peru is in several simultaneous processes for the acquisition of vaccines against coronavirus: the negotiation process with the laboratories that work in the development of vaccines, the Covax Facility alliance through the World Organization of the Health (WHO) and clinical trials in Peru.
Regarding the second process, with the Covax Facility, through which the WHO and the Bill and Melinda Gates Foundation advocate taking vaccines to poor and medium-income countries, the vice minister pointed out that Peru has insured 6.5 million doses, which are equivalent to 20% of the Peruvian population.
He added that some laboratories have also expressed their willingness to offer their vaccines to Peru, such as AstraZeneca, with 10 million doses; Pfizer, with 4 or 5 million, among others.
However, the vice minister specified that it is not yet known exactly which laboratory the vaccines will be purchased from, because everything depends on the results of the phase 3 studies and the certifications that are required to guarantee the safety of the vaccines. persons.
Suárez indicated that preparations for vaccination in Peru have begun with the identification of the population to be vaccinated, logistics, training for vaccinators, transport requirements, cold chain, etc., so that everything is ready when the vaccines arrive.
As recalled, the first peer-reviewed results of phase 1 and phase 2 clinical trials of the Russian coronavirus vaccine, Sputnik-V, were published in the prestigious medical journal The Lancet this Friday.
The results of the two 42-day trials, which each included 38 healthy adults, “They have a good safety profile without serious adverse events” among participants, according to The Lancet. There were vaccine-induced antibody responses in all participants.
He specified that, at first, the vaccine will be applied to people over 60 years of age, to those who suffer from chronic diseases and, simultaneously, to health workers, law enforcement agencies and cleaning personnel who work on the front line battle to reduce severe cases and deaths from coronavirus.
He explained that the results of the clinical trials for minors will only be available at the end of next year, so the vaccination for this age group -which is the lowest risk- will be carried out in 2022.
Finally, Suárez remarked that the Ministry of Health (Minsa) will guarantee effective, free and quality vaccines for the vaccination campaign against COVID-19, which aims to vaccinate 20 million Peruvians over 18 years of age in 2021.